Who
Stephen Mayo
Director
Company insider
Files Form 4 as: Director, Allogene Therapeutics; Director, Sarepta Therapeutics; Director, Merck & Company.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $769K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 15 Mar 2021
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,400 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 29 May 2026filed 2 Jun 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,853.1 at $118.72 | filing |
| 29 May 2026filed 2 Jun 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,853.1 at $118.72 | filing |
| 12 Mar 2026filed 13 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $123K7,239 at $17.02 | filing |
| 12 Mar 2026filed 13 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $123K7,239 at $17.02 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K2,863.09 at $76.84 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,792 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,383 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —191,082 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,752.43 at $125.54 | filing |
| 5 Mar 2024filed 6 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $385K3,135 at $122.96 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,679 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,846 at $0.00 | filing |
| 7 Aug 2023filed 9 Aug 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $43K10,000 at $4.29 | filing |
| 13 Jun 2023filed 15 Jun 2023 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,120 at $0.00 | filing |
| 26 May 2023filed 31 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,980.73 at $111.07 | filing |
News
St. Stephen mayor hopeful as province promises to help with drug situationcbc.ca · 23 Oct 2026Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)SRPT · dailypolitical.com · 22 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026
1 headline in the last 90 days name Stephen Mayo; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.